A Pilot Trial of Interferon Beta-1a in Alzheimer's Disease
Status:
Completed
Trial end date:
2008-05-01
Target enrollment:
Participant gender:
Summary
This was a 52-week, multicentric, phase II, pilot study conducted in 40 subjects with
early-onset Alzheimer's disease (AD) to evaluate safety, tolerability and clinical efficacy
of subcutaneous (sc) interferon (IFN) beta-1a [Rebif® 22 microgram (mcg), three times per
week (tiw)] in the treatment of AD by comparing the neuropsychological performance changes
into placebo and treatment arms from screening/baseline to 52 week.